Twist Bioscience Corporation TWST
At closeNov 6, 2026, 4:50 PM EST
After hours · Nov 6, 4:50 PM ET
- YTD
- +280.80%
- 1 year
- +294.35%
- Market cap
- 8.01B
- Revenue (ttm)
- 431.80M
- Profit margin
- -31.66%
- EPS (ttm)
- -2.23
- Shares out
- 66.30M
- Forward P/E
- -301.98
- YTD return
- +280.80%
- 1-year return
- +294.35%
- Volume
- 2.06M
- Avg volume
- 2.34M
- Open
- 123.83
- Previous close
- 120.61
- Day's range
- 116.50 – 130.90
- 52-week range
- 25.45 – 205.00
- Beta
- 2.22
- Analysts
- Buy
- Price target
- 168.25 (+39.3%)
- Earnings date
- Nov 12, 2026
5D -30.45 (-20.13%)
Key statistics
- Enterprise value
- 7.50B
- PEG ratio
- 0.00
- Price / sales
- 18.55
- Price / book
- 16.98
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.20%
- Free cash flow
- -64.82M
- Total cash
- 166.84M
- Total debt
- 108.59M
- Return on equity
- -29.59%
- Short % of float
- 19.42%
- 50-day average
- 152.00
- 200-day average
- 90.84
Analyst view
Consensus: buy
- Target (low)
- 45.00
- Target (mean)
- 168.25
- Target (high)
- 215.00
- Strong buy2
- Buy7
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.203.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.38452 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.50625 | -0.56 | -0.05 | -10.62% |
| May 4, 2026 | Mar 31, 2026 | -0.49 | -0.71 | -0.22 | -44.90% |
| Feb 2, 2026 | Dec 31, 2025 | -0.48 | -0.50 | -0.02 | -4.17% |
| Nov 14, 2025 | Sep 30, 2025 | -0.50 | -0.45 | +0.05 | +10.00% |
| Aug 4, 2025 | Jun 30, 2025 | -0.54 | -0.47 | +0.07 | +12.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 8, 2026 | Jefferies | init | — | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | main | Outperform | Outperform |
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- twistbioscience.com
News
Twist Bioscience Stock Sinks as Bear Cave Raises Valuation Concerns 
Polen 5Perspectives Growth Opportunities Q3 2026 Portfolio Review 
Polen 5Perspectives Small Growth Composite Q3 2026 Portfolio Attribution And Activity 
Twist Bioscience Proposes Derivative Litigation Settlement Featuring Corporate Governance Reforms And $1M In Legal Fees 
Notice of Proposed Derivative Settlement: Twist Bioscience Corporation 
10 Health Care Stocks Whale Activity In Today’s Session 
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190 
10 Health Care Stocks With Whale Alerts In Today’s Session 
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205 
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Your note
Sign in to keep a note on TWST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN NELSON C | Director | Stock Award(Grant) | Feb 4, 2026 | 33,251 |
| CHESS ROBERT BRUCE | Director | Sale | Aug 6, 2026 | 63,612 |
| CHO DENNIS | Officer | Sale | Nov 2, 2026 | 62,840 |
| CRANDELL KEITH L. | Director | Stock Award(Grant) | Feb 4, 2026 | 103,618 |
| FINN PATRICK JOHN | President | Sale | Nov 2, 2026 | 180,278 |
| GREEN PAULA | Officer | Sale | Nov 2, 2026 | 105,625 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.30% | 5,833,891 | 704.68M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 7.66% | 4,802,017 | 580.04M | Jun 29, 2026 |
| FMR, LLC | 7.50% | 4,703,044 | 568.08M | Jun 29, 2026 |
| ARK Investment Management, LLC | 7.26% | 4,549,803 | 549.57M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.80% | 3,634,652 | 439.03M | Jun 29, 2026 |
| State Street Corporation | 5.15% | 3,232,532 | 390.46M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,874,473 | 226.42M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.95% | 1,847,954 | 223.21M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.73% | 1,714,174 | 207.06M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 1,357,205 | 163.94M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.92% | 1,201,502 | 145.13M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.88% | 1,177,281 | 142.20M | Sep 29, 2026 |